Remibrutinib (LOU064) treatment improves hive severity in patients with chronic spontaneous urticaria: Findings from a Phase 2b study

A. Gimenez-Arnau, K. Hayama, V. Jain, K. Sitz, K. Lheritier, I. Nikolaev, P. Walsh, S. Haemmerle, M. Maurer

Abstract Oral presentation

Long-term treatment with remibrutinib shows favorable safety profile and sustained efficacy in patients with chronic spontaneous urticaria: Final results from a 52-week phase 2b extension study

A. Gimenez-Arnau, J. Tillinghast, V. Jain, S. Haemmerle, K. Lheritier, P. Walsh, S. Hugot, M. Wells, A. Zharkov, W. Carr

Abstract Oral presentation

Remibrutinib (LOU064) treatment improves chronic spontaneous urticaria in patients irrespective of previous anti-IgE treatment: Phase 2b study results

M. Metz, A. Greiner, S. Guduri, J. Leflein, S. Haemmerle, K. Lheritier, P. Walsh, I. Nikolaev, A. Giménez-Arnau, M. Maurer

Abstract Oral presentation

Remibrutinib (LOU064) showed good stability of response in patients with chronic spontaneous urticaria: A novel exploratory analysis of data from the Phase 2b study

M. Maurer, A. Giménez-Arnau, V. Jain, A. Reich, CE. Ortmann, P. Walsh, S. Haemmerle

Abstract Poster

Efficacy, safety, and tolerability of remibrutinib (LOU064) in CSU patients: Study design of Phase 3b extension trial

M. Maurer, A. Giménez-Arnau, S. Saini, M. Lebwohl, G. Sussman, M. Hide, K. Lheritier, A. Zharkov, S. Bhat, L. Wei, ED. Martzloff, S. Haemmerle

Abstract Poster

Divergent Patients' and Physicians' Perceptions of Chronic Urticaria Disease Control: An Urticaria Voices Study Outcome

PA. Laires, MM. Balp, K. Weller, TA. Winders, JA. Bernstein, M. Dricu, S. Flierl, L. Christen, N. Janssens, S. Smeets

Abstract Poster

Prevalence and overall disease burden of chronic spontaneous urticaria in five European countries (France, Germany, Italy, Spain, and United Kingdom)

MM Balp, K Krupsky, BL Balkaran, S Gupta, C Lienhard, D Patil, RK Kohli, JM Rodriguez Barrios, A Romero, F Tétart, J Reed, T El-Shanawany

Abstract Oral presentation

Long-term safety and tolerability of remibrutinib (LOU064) in Phase 2b study in chronic spontaneous urticaria patients

A. M. Giménez-Arnau, M. Maurer, M. Metz, V. Jain, P. Walsh, K. Lheritier, S. Hugot, H. Zouater, S. Haemmerle, A. Zharkov

Abstract Oral Abstract Session

More patients achieve absence of angioedema with remibrutinib (LOU064) than placebo: Results from a dose-finding Phase 2b study

M. Maurer, J. Reed, P. Staubach, K. Lheritier, P. Walsh, I. Nikolaev, S. Haemmerle, A. M. Giménez-Arnau

Abstract Flash Talk Poster Slides

Remibrutinib (LOU064) reduces the use of rescue medication in patients with chronic spontaneous urticaria: Findings from a Phase 2b study

M. Maurer, J. Reed, P. Staubach, K. Lheritier, P. Walsh, V. Meti, I. Nikolaev, S. Haemmerle, A. M. Giménez-Arnau

Abstract Oral Abstract Session

Angioedema control with ligelizumab in patients with chronic spontaneous urticaria correlates with improvement of health-related quality of life

M. Metz, A. M. Giménez-Arnau, M. Maurer, M. Hide, K. Sitz, C-E. Ortmann, M-M. Balp, T. Severin

Abstract Poster Poster Slides

Ligelizumab achieves complete response in chronic spontaneous urticaria patients with or without angioedema at baseline: A composite score evaluation

A. M. Giménez-Arnau , M. Maurer, J. A. Bernstein, G. Sussmann, M. Hide, C-E. Ortmann, T. Severin

Abstract Flash Talk Poster Slides

Ligelizumab is effective in chronic spontaneous urticaria patients with and without serum autoreactivity assessed by basophil histamine release assay

M. Maurer, W. Soong, A. M. Giménez-Arnau, J. A. Bernstein, E. Hua, C-E. Ortmann, T. Severin

Abstract Oral Abstract Session

Long term control of urticaria disease activity with ligelizumab in patients with CSU: data from the Phase 2b extension study

J. A. Bernstein, P. Staubach, M. Maurer, S. Savic, M. Hide, T. Severin, E. Hua

Abstract Flash Talk Poster Slides

Evaluating the implementation and effectiveness of an "Urticaria Care Package" to support the assessment and use of Patient Reported Outcomes in the management of Chronic Spontaneous Urticaria: An implementation science project

P. A. Laires, M. Bartezaghi, O. Bonavita, E. Peruzzi, G. Dasari, N. Janssens, V. Herrera, E. Gibbons, J. N. Hill, I. Nikolaev, S. De Geest

Abstract Poster

Low urticaria control test (UCT) scores are a significant predictor of poor response to antihistamines: analysis from worldwide real-world data (AWARE study)

A. Rajan, P. A. Laires, N. Janssens, S. Rizvi, S. Smeets, K. Weller

Abstract Poster

Comparative economic burden of chronic spontaneous urticaria, psoriasis and atopic dermatitis in five European countries (France, Germany, Italy, Spain, United Kingdom)

S. Gupta, M-M. Balp, S. Walsh, B. L. Balkaran, C. Lienhard, J. Loh, J. M. Rodriguez Barrios, K. Krupsky, A. Romero, T. El-Shanawany, F. Tétart, J. Reed

Abstract Flash Talk

Humanistic burden of chronic spontaneous urticaria relative to psoriasis and atopic dermatitis in five European countries (France, Germany, Italy, Spain, United Kingdom)

M-M. Balp, S. Walsh, B. L. Balkaran, S. Gupta, K. Krupsky, C. Lienhard, J. Loh, J.M. Rodriguez Barrios, A. Romero, F. Tétart, T. El-Shanawany, J. Reed

Abstract Poster

Impact of severity on the economic burden of chronic spontaneous urticaria in five European countries (France, Germany, Italy, Spain, United Kingdom)

M-M. Balp, K. Krupsky, B.L. Balkaran, S. Gupta, C. Lienhard, J. Loh, J. M. Rodriguez Barrios, A. Romero, S. Walsh, J. Reed, T. El-Shanawany, F. Tétart

Abstract Poster

Impact of severity on the humanistic burden of chronic spontaneous urticaria in five European countries (France, Germany, Italy, Spain, United Kingdom)

S. Gupta, M-M. Balp, B. L. Balkaran, K. Krupsky, C. Lienhard, J. Loh, J. M. Rodriguez Barrios, S. Walsh, A. Romero, F. Tétart, J. Reed, T. El-Shanawany

Abstract Poster

Prevalence and clinical profile of patients with chronic inducible urticaria in the EU5 (France, Germany, Italy, Spain, United Kingdom)

M-M. Balp, K. Krupsky, B. L. Balkaran, S. Gupta, C. Lienhard, S. Walsh, J. Loh, J. M. Rodriguez Barrios, A. Romero, F. Tétart, J. Reed, T. El-Shanawany

Abstract Poster

Comorbidity burden and healthcare resource utilization associated with non-response to H₁-antihistamines alone or in combination with non-biologic treatments for chronic spontaneous urticaria

W. Soong, D. Patil, I. Pivneva, R. Bhak, J. Signorovitch, M-M. Balp, K. Freedle

Abstract Poster

Chronic spontaneous urticaria systems biology-based models for the mechanistic evaluation of novel targets

J. Gómez, C. Segú-Vergés, P. Terradas, L. Artigas, S. Smeets, M. Ferrer, S. Savic

Abstract Poster

Systems biology-based mechanistic models support the centrality of mast cell activation and the IgE- FcεRI axis in chronic spontaneous urticaria

J. Gómez, C. Segú-Vergés, P. Terradas, L. Artigas, S. Smeets, M. Ferrer, S. Savic

Abstract Flash Talk

Evaluating the impact of chronic spontaneous urticaria on patients’ lives using social media listening

E. Kocatürk, M. Bizjak, E. S. Baldrich, L. Walter, P. Terradas, L. Christen, N. Janssens, S. Smeets

Abstract Poster Poster Slides

Moderate to severe chronic spontaneous urticaria has a similar quality of life impact to moderate to severe plaque psoriasis: results from the data42 platform to repurpose clinical trial data

I. Nikolaev, N. Barbier, C-E. Ortmann, N. Janssens, N. Chapman-Rothe, N. Hajizadeh, O. Hsine, A. Rajan, P. A. Laires, H. Edgren

Abstract Flash Talk Poster Slides

Symposia

Welcome & Introduction

M. Maurer

 

Chronic Spontaneous Urticaria: defining the pathway to successful management
A panel discussion on overcoming roadblocks to CSU care, based on real life experiences

M. Maurer, E. Kocatürk and S. Savic

 

Live Q&A

M. Maurer, E. Kocatürk and S. Savic

 

2021

Ligelizumab achieves fast control of symptoms in patients with chronic spontaneous urticaria: A rolling UAS7 analysis

M. Maurer, A. M. Giménez-Arnau, W. Soong, M. Hide, J. A. Bernstein, S. Acharya, A. Barve, T. Severin

Abstract Poster Poster slides

Evaluating complete control of urticaria with ligelizumab: A composite score of symptoms and quality-of-life outcome

A. M. Giménez-Arnau, M. Maurer, J. A. Bernstein, K. Sitz, G. Sussman, S. Acharya, P. Terradas-Montana, T. Severin

Abstract Poster Poster slides

Predicting time to natural remission in chronic urticaria using random survival forest model

I. Pivneva, M-M Balp, Y. Geissbühler, A. Danyliv, T. Severin, S. Smeets, J. Signorovitch, J. Royer, Y. Liang, T. Cornwall, J. Pan, A. Marsland, W. Soong

Abstract Poster

Factors influencing natural remission in chronic urticaria – preliminary results from a machine learning real-world study

M-M. Balp, I. Pivneva, Y. Geissbühler, T. Severin, S. Smeets, J. Signorovitch, J. Royer, Y. Liang, T. Cornwall, J. Pan, A. Danyliv, W. Soong, A. Marsland

Abstract Poster

Prevalence and incidence of diagnosed chronic inducible urticaria (CIndU) in the insured US population: A real-world study using claims data

M-M. Balp, Y. Geissbühler, A. Mcconnon, J. Schäl, J. Gomme, S. Pal, S. J. McKenna, P. A. Laires, W. Soong

Abstract Poster

Prevalence and incidence of diagnosed chronic spontaneous/idiopathic urticaria (CSU/CIU) in the insured US population: a real-world study using claims data

Y. Geissbühler, M-M. Balp, A. Mcconnon, J. Schäl, J. Gomme, S. Pal, S. J. McKenna, P. A. Laires, W. Soong

Abstract Poster

Symposia

Why do our patients fail to reach complete control?

Z. Brzoza

 

How can targeting IgE contribute to complete control?

M. Maurer

 

2020

Study design and rationale of a phase 3b extension study of ligelizumab in adult and adolescent patients with chronic spontaneous urticaria

T. Severin, M. Maurer, A. M. Giménez-Arnau, M. Hide, G. Sussman, S. S. Saini, E. Hua, A. Barve, Y. Joubert, I. Indermuehle, R. Janocha

Abstract Poster Poster slides

Long-term treatment with ligelizumab achieves prolonged symptom control in chronic spontaneous urticaria patients during the post-treatment follow-up

W. Soong, M. Metz, J. A. Bernstein, G. Sussman, B. Lanier, K. Sitz, M. Maurer, A. M. Giménez-Arnau, E. Hua, A. Barve, T. Severin, R. Janocha

Abstract Poster Poster slides

Treatment with ligelizumab achieves over forty percent higher complete response rate in chronic spontaneous urticaria patients originally treated with omalizumab

M. Maurer, A. M. Giménez-Arnau, W. Soong, J.A. Bernstein, G. Sussman, M. Metz, B. Lanier, M. Hide, K. Sitz, E. Hua, A. Barve, T. Severin, R. Janocha

Abstract Oral presentation

Disease control correlates with improvement of dermatology quality of life in CSU patients with angioedema treated with ligelizumab

A. M. Giménez-Arnau, M. Maurer, W. Soong, J. A. Bernstein, G. Sussman, M. Metz, B. Lanier, M. Hide, K. Sitz, E. Hua, P. Gupta, A. Barve, T. Severin, R. Janocha, M. Balp

Abstract Poster Poster slides

Ligelizumab achieves high rate of complete responses in patients with moderate to severe chronic spontaneous urticaria

A. J. Bernstein, M. Maurer, A. M. Giménez-Arnau, W. Soong, G. Sussman, M. Metz, B. Lanier, K. Sitz, M. Hide, E. Hua, A. Barve, T. Severin, R. Janocha

Abstract Oral presentation

Symposia

IgE inhibition in CSU: Not all anti-IgEs are born equal

A. Eggel

Slides

IgE inhibition implications: How does this benefit patients with chronic spontaneous urticaria?

M. Maurer

Slides

2019

Ligelizumab achieves sustained control of chronic spontaneous urticaria symptoms of hives, itch and angioedema: 1-year treatment results

J.A. Bernstein, D. Baker, M. Maurer, A. Giménez -Arnau, G. Sussman, A. Barve, E. Hua, T. Severin, R. Janocha

Abstract Oral Presentation

LOU064: A highly selective and potent covalent oral BTK inhibitor with promising pharmacodynamic effects in skin

M. Kaul, J. Storim, P. End, M. Cabanski, A. Jakab, C. Schuhler, E. Funhoff, F. Schaefer, E. Dimanova, M. Kistowska, A. Kinhikar, A. Maiolica, A. Sinn, R. Fuhr, B. Cenni

Abstract Oral Presentation

Ligelizumab is well tolerated and exhibits a safety profile similar to omalizumab and placebo in patients with chronic spontaneous urticaria

G. Sussman, M. Maurer, A. M. Giménez-Arnau, E. Hua, T. Severin, R. Janocha

Abstract Oral Presentation

Ligelizumab retreatment is highly effective in patients with chronic spontaneous urticaria

M. Maurer, A. M. Giménez-Arnau, G. Sussman, E. Hua, T. Severin, R. Janocha

Abstract Oral Presentation

2018

Ligelizumab as add-on therapy for patients with H1-antihistamine-refractory chronic spontaneous urticaria: Primary results of a placebo- and active-controlled, phase 2b dose-finding study

M. Maurer, A. Giménez -Arnau, G. Sussman, J. Loeffler, A. Barve, T. Severin, R. Janocha

Abstract Poster